Rachel McKendry height - How tall is Rachel McKendry?

Rachel McKendry (Rachel Anne McKendry) was born on 1973 in British, is a British chemist and digital public health pioneer. At 47 years old, Rachel McKendry height not available right now. We will update Rachel McKendry's height soon as possible.

Now We discover Rachel McKendry's Biography, Age, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is She in this year and how She spends money? Also learn how She earned most of net worth at the age of 49 years old?

Popular As Rachel Anne McKendry
Occupation N/A
Rachel McKendry Age 49 years old
Zodiac Sign N/A
Birthplace N/A
Nationality British

We recommend you to check the complete list of Famous People born on . She is a member of famous with the age 49 years old group.

Rachel McKendry Weight & Measurements

Physical Status
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

She is currently single. She is not dating anyone. We don't have much information about She's past relationship and any previous engaged. According to our Database, She has no children.

Parents Not Available
Husband Not Available
Sibling Not Available
Children Not Available

Rachel McKendry Net Worth

She net worth has been growing significantly in 2021-22. So, how much is Rachel McKendry worth at the age of 49 years old? Rachel McKendry’s income source is mostly from being a successful . She is from British. We have estimated Rachel McKendry's net worth , money, salary, income, and assets.

Net Worth in 2022 $1 Million - $5 Million
Salary in 2022 Under Review
Net Worth in 2021 Pending
Salary in 2021 Under Review
House Not Available
Cars Not Available
Source of Income

Rachel McKendry Social Network

Wikipedia Rachel McKendry Wikipedia



McKendry says she is most proud of her Interdisciplinary research team and breakthroughs in nanosensors for antibiotic drug discovery and early disease diagnosis. In 2015, she presented a Ted Talk in Exeter on "The Digital Future of Public Health", in which she discussed early warning systems for disease outbreaks – from Sars to Ebola – being developed along the lines of Google Flu Trends, based on anonymised social media chatter from the world's many billion users of Smart Phones and other digital devices.

Such basic scientific advances are among those required for the future of smart phone-based, low cost, rapid-result infectious disease test kits of the kind McKendry described in her 2015 TEDx talk. "The grand challenge now," said McKendry in a Nature Nanotechnology News and Views article in 2015, "will be to integrate nanosensors onto... cost-effective point-care devices that can examine clinically problematic bacteria in a variety of community settings, including doctors surgeries and developing countries."


In 2014, also in Nature Nanotechnology, McKendry, and her co-workers, Joseph Ndieyira et al, used nano sensors to test a theoretical approach to personalised antibiotic treatment for individual patients of the future. Their prototype nano-mechanical sensors measured the amount of antibiotic freely available to target bacteria in human blood plasma, which contains serum proteins that also bind weakly to antibiotics, neutralising their effect against bacteria. This study mimicked an aspect of the complex physiology of human blood in a living patient. and was used to compare effectiveness of a novel antibiotic, oritavancin with the older antibiotic, vancomycin (which is threatened by evolving antimicrobial resistance). 'Perhaps the most obvious diagnostic application,' the researchers concluded 'is to measure the active free drug availability in blood for a particular medical target and thereby determine appropriate doses tailored for individualised patients.'

In 2014 McKendry received a Royal Society Wolfson Research Merit Award, to assist her study of 'New Paradigms in Connected Global Health for Infectious Diseases.'

In 2014, she received a Royal Society Rosalind Franklin Award for her 'scientific achievements, her suitability as a role model and for her exciting proposal to launch a national competition to create mobile phone apps to inspire women to become leaders in science, technology, engineering and mathematics (STEM)'.


In 2009 McKendry was awarded the Institute of Physics Clifford Paterson Medal and Prize.


In 2008, writing in Nature Nanotechnology with colleagues from labs in the UK, Kenya and Australia, she showed how nano-sensors could 'feel' mechanical stresses in the cell walls of bacteria when the antibiotic Vancomycin attaches to them. Vancomycin was used in the study as it is one of the last powerful antibiotics in the battle against resistant bacteria and the 'hospital superbug' ... MRSA the paper explained. Nanosensors used in the study showed that it was approximately 1,000 times harder for Vancomycin to attach to the cell walls of antibiotic-resistant 'Superbugs.' Understanding the process by which Vancomycin attaches (or fails to attach) to bacterial walls and weakens or kills bacteria, led researchers in this study to suggest other, potentially more effective alternatives compounds worthy of investigation.


After working as a postdoctoral researcher at the IBM Zurich Research Laboratory, McKendry returned to the UK in 2001 to take up the Royal Society's Dorothy Hodgkin Research Fellowship and work at University College London.


At Cambridge, McKendry was a member of the University Women's Boat Club and in 1997 was part of its winning 'Blondie' crew, beating Oxford's Osiris team.


McKendry was born in London, the daughter of an engineer and a civil servant. She went to a comprehensive school before studying chemistry at Durham University (Trevelyan College), graduating in 1994. She was awarded a PhD from University of Cambridge in 1999, and won a Girton College, Cambridge Research Fellowship in 1998.


Rachel Anne McKendry (born 1973) is a British chemist and digital public health pioneer. She is Director of i-sense, a UK-based interdisciplinary research collaboration developing early warning sensing systems for infectious diseases. Rachel is also Professor of Biomedical and Nanotechnology at University College London and the London Centre for Nanotechnology. She is part of the UK's Cross Council Initiative on Antimicrobial Resistance.